Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ziihera
Pharma
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
“What is clear is that we have found a better way to target HER2,” an ASCO-invited expert said, referring to Ziihera as better than Herceptin.
Angus Liu
Jan 6, 2026 3:25pm
Zymeworks pivots to become 'royalty-driven' drugmaker
Nov 18, 2025 8:25am
Jazz reviewing M&A deal options of 'various sizes,' CFO says
Feb 26, 2025 11:08am
Jazz hunts for new CEO as longtime chief Cozadd eyes retirement
Dec 17, 2024 10:49am
Jazz's HER2 bispecific snags FDA nod to rival Enhertu
Nov 21, 2024 7:53am
